Abstract
The goal of diabetes management is to achieve a normal blood glucose level as the basis for the prevention of severe delayed complications. A major risk of intensive therapy is an increased hypoglycemia risk.
Gliptins are a novel class of antidiabetic agents that increase endogenous GLP-1 levels by DPP-4 inhibition. They have comparable clinical efficacy as other oral anti-diabetic drugs and a very good safety profile, in particular a very low hypoglycemia risk.
They highly probably have a positive effect even on the cardiovascular risk. Sitagliptin, vildagliptin, saxagliptin, and linagliptin have been registered in the Czech Republic.